Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 6/20 | 0.50 |
| ▸ | ADH1C | P00326 | 4/20 | 0.47 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9660549 | 1.00 | ADH1A (0.50) | ADH1AADH1CADH1BCYP1A2THRA | |
| SCHEMBL9660999 | 1.00 | ADH1A (0.50) | ADH1AADH1CADH1BCYP1A2THRA | |
| SCHEMBL3024929 | 0.98 | ADH1A (0.48) | ADH1AADH1C | |
| SCHEMBL11564214 | 0.89 | — | — | |
| SCHEMBL303074 | 0.88 | ADH1A (0.43) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL9660873 | 0.88 | ADH1A (0.43) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL9658873 | 0.88 | ADH1A (0.43) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL11166960 | 0.86 | ADH1A (0.42) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL9661149 | 0.86 | ADH1A (0.41) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL302802 | 0.83 | ADH1A (0.47) | ADH1AADH1CADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8093422-B2 | Method for deuteration of an aromatic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-7517990-B2 | Method for deuteration of a heterocyclic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1707548-A1 | METHOD OF DEUTERATION USING MIXED CATALYST | Wako Pure Chemical Industries, Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20060116535-A1 | Method of deuteration | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577280-A1 | METHOD OF DEUTERIZATION | Wako Pure Chemical Industries, Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1535889-A1 | METHOD OF DEUTERATING AROMATIC RING | Wako Pure Chemical Industries, Ltd. (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| US-6200974-B1 | FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT | ZENECA LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
| WO-1997047599-A1 | SUCCINAMIDE DERIVATIVES USEFUL AS TNF- AND/OR MMP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-12-18 | — | — | WO | disclosed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5430022-A | Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| US-5284828-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0023569-B1 | DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1983-06-22 | — | — | EP | disclosed |
| EP-0023569-A1 | Derivatives of carboxylic acids, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | HDHD5, DHX35, HRH3 | ADH1A 1333/4885ADH1C 1044/4885ADH1B 502/4885 |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | HRH3, HRH4, AHR | ADH1A 823/4885ADH1C 1127/4885ADH1B 501/4885 |
| US-20060116535-A1 | Method of deuteration | ARL1, IDH2, IDH3A | ADH1A 302/4885ADH1C 186/4885ADH1B 477/4885 |
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | ADH1A 293/4885ADH1C 24/4885ADH1B 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.